From September, 2017, WHO will accept applications for prequalification into their Essential Medicines List for biosimilar versions of two biologics: rituximab (for non-Hodgkin's lymphoma) and trastuzumab (for breast cancer). This pilot project is an effort to increase access to these costly cancer treatments in low-income countries.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2r5yRh3
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Objectives Adult sagittal posture is established during childhood and adolescence. A flattened or hypercurved spine is associated with poore...
-
Publication date: Available online 10 May 2017 Source: Journal of Dairy Science Author(s): R.E. Vibart, M. Tavendale, D. Otter, B.H. Schw...
-
Epidemiology and predictive factors of fungal malignant otitis externa Rim Bechraoui, Mohamed Dhaha, Houda Chahed, Amal Ksentini, Rim Zainin...
-
Abstract Background Histamine intolerance is thought to trigger manifold clinical symptoms after ingesting histamine-rich food due to re...
-
Abstract Purpose Gastric cancer (GC) is one of the fatal malignancies worldwide with high occurrences but poor outcomes. bFGF has been s...
-
ACS Nano DOI: 10.1021/acsnano.6b07082 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2j1vZRU via...
-
Family: Know the drill New Straits Times Online One of my sons had this so often that his tonsils were removed. ... However, for som...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου